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Abstract
Background: Identification of CYP2A6 alleles associated with reduced enzyme activity is important
in the study of inter-individual differences in drug metabolism. CYP2A6*12 is a hybrid allele that
results from unequal crossover between CYP2A6 and CYP2A7 genes. The 5' regulatory region and
exons 1–2 are derived from CYP2A7, and exons 3–9 are derived from CYP2A6. Conventional
methods for detection of CYP2A6*12 consist of two-step PCR protocols that are laborious and
unsuitable for high-throughput genotyping. We developed a rapid and accurate method to detect
the CYP2A6*12 allele by Pyrosequencing technology.
Methods: A single set of PCR primers was designed to specifically amplify both the CYP2A6*1 wild-
type allele and the CYP2A6*12 hybrid allele. An internal Pyrosequencing primer was used to
generate allele-specific sequence information, which detected homozygous wild-type,
heterozygous hybrid, and homozygous hybrid alleles. We first validated the assay on 104 DNA
samples that were also genotyped by conventional two-step PCR and by cycle sequencing.
CYP2A6*12 allele frequencies were then determined using the Pyrosequencing assay on 181 multi-
ethnic DNA samples from subjects of African American, European Caucasian, Pacific Rim, and
Hispanic descent. Finally, we streamlined the Pyrosequencing assay by integrating liquid handling
robotics into the workflow.
Results: Pyrosequencing results demonstrated 100% concordance with conventional two-step
PCR and cycle sequencing methods. Allele frequency data showed slightly higher prevalence of the
CYP2A6*12 allele in European Caucasians and Hispanics.
Conclusion: This Pyrosequencing assay proved to be a simple, rapid, and accurate alternative to
conventional methods, which can be easily adapted to the needs of higher-throughput studies.
Background
Cytochrome P450 (CYP) is a diverse superfamily of
enzymes that catalyzes the metabolism of a wide variety of
compounds, including drugs and xenobiotics [1]. CYP2A6
is a member of this superfamily. It was first identified as
the human coumarin 7-hydroxylase enzyme [2]. CYP2A6
is also the primary enzyme responsible for the metabo-
lism of nicotine to cotinine. Substantial inter-individual
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and inter-ethnic differences in enzyme activity are thought
to be attributable to genetics as well as to environmental
factors [3]. Individuals lacking a functional CYP2A6 gene
have impaired nicotine metabolism and are therefore less
prone to nicotine addiction and possibly tobacco-related
cancers [4].
The CYP2A6 gene is located on chromosome 19, adjacent
to the inactive and highly homologous CYP2A7 gene. Of
the 17 different allelic variants in CYP2A6  that are
reported to abolish or decrease enzymatic activity, five are
the result of unequal crossover and gene conversion
events between CYP2A6  and  CYP2A7  [5]. The hybrid
CYP2A6*12 allele is the product of such a crossover event;
it contains the 5' regulatory region and exons 1–2 of the
CYP2A7 gene and exons 3–9 of the CYP2A6 gene. The
overall effect is a change in 10 amino acids and a reduc-
tion in enzyme activity [6].
The method currently used to genotype CYP2A6*12
involves a two-step PCR [6]. The first step (PCR I) ampli-
fies a 2.3 kb fragment encompassing a region from 240 bp
upstream of the start codon to exon 3. This method uses a
forward primer that binds to a site that is identical in both
CYP2A6 and CYP2A7 gene sequences. However, amplifi-
cation of the CYP2A7 gene is prevented by use of a reverse
primer that is specific for CYP2A6 exon 3 sequence. Thus,
the primer set can amplify both CYP2A6*1 wild-type and
CYP2A6*12 variant but not the CYP2A7 gene. The PCR I
product serves as a template for two separate allele-spe-
cific PCR reactions (PCR II). Genotype determination is
by gel electrophoresis of allele-specific products for
CYP2A6*1 and CYP2A6*12. Although accurate and relia-
ble, this method is not practical for use in large popula-
tion screening.
The aim of this study was to design a Pyrosequencing
assay to genotype the CYP2A6*12 hybrid allele that could
be adapted to higher-throughput studies. The unique
sequence structure of the hybrid allele lends itself to this
technology. The Pyrosequencing method involves solu-
tion-based fluorescent real-time DNA sequencing
whereby a sequencing primer is hybridized to a single-
stranded PCR amplicon that serves as a template for
sequential polymerase-catalyzed incorporation of nucle-
otides. Each incorporation event facilitates a cascade of
enzymatic reactions that generates light displayed as a
series of peaks (Pyrogram® traces) representative of the
nucleotide sequence. The Pyrosequencing method has
been used for many applications, such as SNP genotyping
[7], DNA methylation analysis [8], and gene copy number
assessment [9,10].
Methods
Subjects
DNA samples from 90 individuals of the Polymorphism
Discovery Resource (PDR) and 14 individuals of a multi-
generational Centre d'Etude du Polymorphisme Humain
(CEPH)/Utah family (Coriell Cell Repositories, Camden,
NJ) were used to optimize and validate the Pyrosequenc-
ing assay. An additional 181 samples from the Coriell
SNP500 panel and the NIGMS Human Variation panels
HD24AA, HD24EC, HD24CHI, and HD07 Japanese
http://ccr.coriell.org/Sections/Collections/NIGMS/Popu
lations.aspx?PgId=177 were genotyped using the vali-
dated Pyrosequencing assay to assess multi-ethnic varia-
tion in frequency of the CYP2A6*12 allele. The combined
panels included African Americans (n = 47), European
Caucasians (n = 48), Pacific Rim (n = 54), and Hispanics
(n = 32). The repository retains no links to individuals,
and the Coriell Institutional Review Board reviews the
procedures of the repository annually. In addition, 7,159
participants aged 12 years or older from Phase 2 (1991–
1994) of the Third National Health and Nutrition Exami-
nation Survey (NHANES III) [11] were screened using the
Pyrosequencing assay to facilitate automation into the
workflow. Use of these samples for this study was
approved by the Centers for Disease Control and Preven-
tion (CDC)/National Center of Health Statistics (NCHS)
Institutional Review Board. Since the initial informed
consent for use of participant blood for research did not
include genetics, the CDC/NCHS Ethics Review Board
approved a revised plan in 2001 which allows for the link-
age of genetic results to NHANES data through the NCHS
Research Data Center to ensure that confidentiality of
study participant's identity is maintained [12].
Assay Design and Validation
The Pyrosequencing assay was designed on the basis of
sequences for the CYP2A6 and CYP2A7 genes obtained
from the Ensembl Gene ID ENSG00000213052 and
ENSG00000198077 databases, respectively [13]. The two
sequences were aligned from 240 bp upstream of the start
codon up to and including 25 bp of exon 3 to locate suit-
able PCR primer regions to specifically amplify CYP2A6*1
and CYP2A6*12 alleles but not the CYP2A7 gene. The for-
ward PCR primer is located upstream of exon 2 and targets
a region that is identical in both CYP2A6 and CYP2A7
sequences. The 3'-biotinylated reverse primer is specific to
CYP2A6 sequence and binds to the beginning of exon 3.
The reverse primer does not bind to the CYP2A7 sequence
because of the presence of two neighboring nucleotide
mismatches in the primer binding site. The specificities of
the PCR primers and the primer melting temperatures
were verified by use of the NCBI BLAST server http://
www.ncbi.nlm.nih.gov/BLAST/.BMC Medical Genetics 2009, 10:80 http://www.biomedcentral.com/1471-2350/10/80
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The internal forward sequencing primer is nested just
downstream of the forward PCR primer in intron 1. It con-
tains two degenerate nucleotides to enable the primer to
hybridize to both CYP2A6*1  and  CYP2A6*12-specific
PCR products that differ from each other by two nucle-
otides at the primer binding site. The sequencing primer is
positioned to interrogate two key nucleotide sites that
allow for clear distinction between CYP2A6*1  and
CYP2A6*12  alleles. Primer location and sequences are
described in Figure 1.
PCR amplification was performed by use of the HotStar-
Taq Master Mix kit with Q solution (Qiagen, Valencia,
CA). The 25 μl PCR reaction contained 20 ng DNA, 0.4
μM of each primer, 1× HotStarTaq Master Mix, and 1× Q-
solution. Amplification was performed with initial dena-
turation at 95°C for 15 min, followed by 40 cycles of
95°C for 30 sec, 58°C for 30 sec, 72°C for 90 sec, and a
final 72°C extension for 2 min 30 sec. PCR products (15
ul) were processed in a 96-well format for Pyrosequencing
analysis by use of a Vacuum Prep Workstation, following
the standard manufacturer's protocol (Biotage AB, Upp-
sala, Sweden). Single-stranded DNA was prepared by cap-
ture of the biotinylated strands onto steptavidin-coated
Sepharose beads (GE Healthcare, Piscataway, NJ) with
subsequent removal of non-biotinylated single strands.
The bead-DNA complex was treated with ethanol, dena-
turation buffer, and wash buffer and released into a Pyro-
Mark Q96 plate containing a mixture of annealing buffer
and 0.8 μM sequencing primer. The plate was incubated at
80°C on a heat block for 2 minutes, followed by a slow
cool for an additional 5 minutes by turning off the heat
block. The plate was transferred directly into a Biotage
PSQ 96HSA System for sequence determination. Data
were analyzed with PSQ HS 96 SNP software that auto-
matically scores genotypes by using a novel SNP algo-
rithm based on comparison of real-time sequence output
(Pyrogram traces) with a theoretical histogram.
Alignment of DNA sequence for CYP2A6*1 and CYP2A6*12 Figure 1
Alignment of DNA sequence for CYP2A6*1 and CYP2A6*12. Arrows indicate forward PCR and sequencing primers (5'-
CTCCCTCTAACCACTCCCAC-3' and 5'-CACYCRCCTCCATCAG-3') and 3'-biotinylated reverse primer (5'-GCTC-
CCCGTTGCTGAATA-3'). The resulting 1274 bp PCR product is specific to CYP2A6*1 and CYP2A6*12 alleles. Exon 2 and 3 
sequences are shown in bold, and the black boxes represent sequence differences between the two alleles that generate allele-
specific peaks in the pyrosequencing reaction. Nucleotide numbering positions for both introns and exons are in reference to 
nucleotide 1, which is the A of the ATG start codon.BMC Medical Genetics 2009, 10:80 http://www.biomedcentral.com/1471-2350/10/80
Page 4 of 6
(page number not for citation purposes)
A two-phase approach was used to genotype the 90 Cori-
ell PDR DNA samples prior to analysis by the Pyrose-
quencing assay. First, the conventional two-step PCR
method was performed as previously described [6]. The
PCR I product from this method was also directly
sequenced through use of the ABI PRISM BigDye Termina-
tor v1.1 cycle sequencing kit (Applied Biosystems, Foster
City, CA). A reverse sequencing primer (5'-AGACTCT-
GGTCCACACTGGTCAA-3') in intron 1 was designed to
capture all sequence differences between CYP2A6*1 and
CYP2A6*12 in exon 1.
CYP2A6*12 Allele Frequency Determination
The Pyrosequencing assay was used to assess multi-ethnic
variation in frequency of the CYP2A6*12 allele by geno-
typing individuals from the African American, European
Caucasian, Pacific Rim, and Hispanic population groups.
For accurate assessment of allele frequency, it was impor-
tant to look at CYP2A6  copy number, since the entire
CYP2A6 gene can be deleted [14]. The gene copy number
was determined by use of a TaqMan assay, as previously
described [15]. This assay uses a FAM-labeled probe spe-
cific to CYP2A6  and a VIC-labeled probe specific to
CYP2A7 that serves as an internal reference for 2 copies.
Automation of the Pyrosequencing Workflow
The Pyrosequencing assay was used to screen 7,159 indi-
viduals from the Third National Health and Nutrition
Examination Survey (NHANES III) as part of a larger study
of genetic variation in xenobiotic metabolizing enzymes
(manuscript in preparation). To accommodate the large
number of samples, robotics were integrated into the
Pyrosequencing strategy and results for CYP2A6 *1 and CYP2A6*12 alleles Figure 2
Pyrosequencing strategy and results for CYP2A6 *1 and CYP2A6*12 alleles. A) Schema of CYP2A6 *1 and CYP2A6*12 
template sequences; arrows indicate forward PCR and sequencing primers, with degenerate nucleotide positions underlined. 
The two allele-specific nucleotides are boxed. B) Predicted histogram and pyrograms for CYP2A6*1/*1 (i), CYP2A6*1/*12 (ii), 
and CYP2A6*12/*12 (iii). Nucleotide dispensation order is shown at the bottom of pyrogram iii. Dispenses 2 and 3 interrogate 
the first allele-specific nucleotide (A in CYP2A6 *1 or T in CYP2A6*12), and dispenses 12 and 13 interrogate the second allele-
specific nucleotide (C in CYP2A6 *1 or T in CYP2A6*12). Dispenses 1, 4, and 14 (circled) serve as negative background controls.
(i)
A/A C/C
A/T C/T
T/T T/T
(ii)
(iii)
CYP2A-F
CYP2Aseq-F
A
CYP2A6*1  CTCCCTCTAACCACTCCCACCCACCTCCATCAG A TCAGTGAG C GC
CYP2A6*12 CTCCCTCTAACCACTCCCACTCGCCTCCATCAG T TCAGTGAG T GC
BBMC Medical Genetics 2009, 10:80 http://www.biomedcentral.com/1471-2350/10/80
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workflow. Increased genotyping throughput and accuracy
of sample handling was accomplished by use of the
Matrix Hydra DT (Thermo Fisher Scientific, Hudson, NH)
to prepare 96-well plates of DNA. The DNA samples were
allowed to dry and were stored at room temperature until
needed. A Matrix WellMate (Thermo Fisher Scientific,
Hudson, NH) was used for multiple dispensing steps
throughout the process such as dispensing of PCR master-
mix into PCR plates, dispensing of the bead mix for bioti-
nylated PCR capture, and dispensing of the annealing
buffer and sequencing primer mix into the PyroMark Q96
plate. In addition, the robotic arm of the PSQ 96HSA sys-
tem was used for multiple plate testing.
Results and discussion
Pyrosequencing assay genotype results were 100% con-
cordant with those obtained by conventional two-step
PCR and cycle sequencing for the 90 PDR and 14 CEPH
family members. The PDR is a multi-ethnic collection of
unrelated individuals designed to serve as a resource for
polymorphism discovery. No phenotypic or ethnic infor-
mation is linked to the individual samples [16]. It also
provides a robust source of DNA material for assay opti-
mization and validation. Genotyping results generated for
the CEPH multi-generational family pedigree displayed
Mendelian inheritance patterns. This satisfied the valida-
tion of our Pyrosequencing assay and provided us with
samples to use as positive controls for future CYP2A6*12
genotyping. Pyrosequencing strategy and representative
Pyrogram results for each genotype are shown in Figure 2.
Results of the multi-ethnic variation panel are shown in
Table 1. There was a higher allele frequency of CYP2A6*12
in Hispanics and Caucasians, with very low occurrence in
African Americans and Asians, as has been reported previ-
ously [6,17]. Use of the TaqMan assay allowed us to calcu-
late our CYP2A6*12  allele frequency against a known
copy number background. This was of particular impor-
tance in the Pacific Rim group where 7 individuals had
only one copy of the CYP2A6 gene. Frequencies in all eth-
nic groups were in Hardy-Weinberg equilibrium. None of
these samples were homozygous for CYP2A6*12. How-
ever, when the assay was used to screen the 7,159 DNA
samples from the NHANES III population, five Mexican-
American and non-Hispanic white participants were
found to be homozygous for CYP2A6*12. These results
were further confirmed by the two-step PCR method.
The addition of robotics into the workflow to facilitate
screening of the NHANES III DNA samples greatly stream-
lined the process. Because of the 96-well format, the Pyro-
sequencing technology is amenable to a high degree of
automation. Use of the robotic arm of the 96HSA system
allowed for the transfer of up to ten 96-well plates for
unattended operation. Data acquisition and analysis of
each batch of ten plates subsequent to placement into the
robotic mechanism was obtained in less than 2 hours.
In summary, we developed a single PCR-based Pyrose-
quencing assay for rapid detection of the CYP2A6*12
hybrid allele. Similar to conventional DNA sequencing,
Pyrosequencing assays generate sequence data but with-
out the need of a cycle sequencing step, expensive fluores-
cent dyes, or gel matrix; moreover, data are accessible in
real-time. The assay, which is dependent upon amplifica-
tion of highly specific PCR templates for wild-type and
hybrid alleles, generates reliable substrates by which one
can unequivocally identify CYP2A6*12 alleles.
Table 1: CYP2A6*12 genotype and allele frequencies by ethnicity as determined by Pyrosequencing
Genotypes Allelesb Published CYP2A6*12 allele frequencies (# alleles tested)ref.
CYP2A6 CYP2A6 CYP2A6
Population *1/*1a *1/*12 *12/*12 CYP2A6*1 CYP2A6*12
African American 100% 0% 0% 100% 0% 0.4% (n = 268)17
(n = 47) (n = 47) (n = 0) (n = 0) (n = 92) (n = 0)
European Caucasian 98% 2% 0% 99% 1% 2% (n = 1440)17
(n = 48) (n = 47) (n = 1) (n = 0) (n = 94) (n = 1)
Pacific Rimc 100% 0% 0% 100% 0% 0% (n = 194)6
(n = 54) (n = 52) (n = 0) (n = 0) (n = 97) (n = 0) 0.3% (n = 354)17
Hispanicd 90.60% 9.40% 0% 95.30% 4.70% 2.2% (n = 184)6
(n = 32) (n = 29) (n = 3) (n = 0) (n = 61) (n = 3)
a CYP2A6*1 refers to alleles without CYP2A6*12. bNumber of alleles based on copy number for CYP2A6. There were individuals with only one copy 
of CYP2A6 in African Americans (n = 2), European Caucasians (n = 1), and Pacific Rim (n = 7). Two individuals from the Pacific Rim were 
homozygous for the CYP2A6 gene deletion and were not included in the frequency data. cThe Pacific Rim includes Japanese, Chinese, Taiwanese, 
Melanesian, and Indo Pakistan. dThe Hispanic population is representative of the Mexican-American community of Los Angeles for this study and of 
a region in northern Spain for the referenced published study.Publish with BioMed Central    and   every 
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Conclusion
A two-step PCR is the predominant method of detection
of the CYP2A6*12  hybrid allele. The Pyrosequencing
assay presented here offers a rapid alternative to the signif-
icantly longer conventional method. The integration of
liquid handling robotics into the workflow helps reduce
errors and further streamlines the process. This approach
provides a substantial decrease in laboratory effort and
can help facilitate analysis of this variant in large popula-
tions used in epidemiological and pharmacogenomic
studies.
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